12:00 AM
Apr 06, 2009
 |  BioCentury  |  Finance

1Q approvals

1Q approvals

Company Approval
Amgen Inc. (NASDAQ:AMGN) EC approves Nplate romiplostim to treat chronic idiopathic thrombocytopenic purpura (ITP) in splenectomised adults who are refractory to other therapies. Nplate also approved as second-line therapy in non-splenectomised patients where surgery is contraindicated.
AstraZeneca plc (LSE:AZN; NYSE:AZN) FDA approves Symbicort budesonide/formoterol to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
CSL Ltd. (ASX:CSL) FDA approves Riastap human fibrinogen concentrate to treat bleeding in patients with congenital fibrinogen deficiency
CSL Ltd. (ASX:CSL)/Intercell AG (VSE:ICLL)/ Novartis AG (NYSE:NVS; SIX:NOVN) Japanese encephalitis (JE) vaccine receives approval in the U.S. and Australia. European approval granted in...

Read the full 603 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >